Literature DB >> 24634148

Dysphagia due to inclusion body myositis: case presentation and review of the literature.

Ellen H Ko1, Adam D Rubin2.   

Abstract

OBJECTIVE: This report aimed to present a case of inclusion body myositis presenting with dysphagia and to review the literature.
METHODS: Case report and literature review.
RESULTS: Inclusion body myositis is a chronic progressive acquired myopathy, uniquely distinguished by its selective muscle involvement, normal or moderately elevated muscle enzyme concentrations, and a progressive corticosteroid-resistant course. Compared to other inflammatory myopathies, the esophagus is the most commonly involved organ. Specifically, upper esophageal sphincter dysfunction often occurs. Dysphagia may be the only symptom at the time of presentation.
CONCLUSION: Unlike other inflammatory myopathies, dysphagia in inclusion body myositis is steroid resistant. Management can be difficult. The otolaryngologist must consider underlying neuromuscular processes when evaluating the patient presenting with oropharyngeal dysphagia.
© The Author(s) 2014.

Entities:  

Keywords:  dysphagia; flexible endoscopic evaluation of swallowing; inclusion body myositis; myopathy; myotomy

Mesh:

Year:  2014        PMID: 24634148     DOI: 10.1177/0003489414525588

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  5 in total

Review 1.  Oropharyngeal dysphagia: manifestations and diagnosis.

Authors:  Nathalie Rommel; Shaheen Hamdy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

2.  Dysphonia and dysphagia as early manifestations of autoimmune inflammatory myopathy.

Authors:  Samuel F Weinreb; Krzysztof Piersiala; Alexander T Hillel; Lee M Akst; Simon R Best
Journal:  Am J Otolaryngol       Date:  2020-10-03       Impact factor: 1.808

Review 3.  Immune and myodegenerative pathomechanisms in inclusion body myositis.

Authors:  Christian W Keller; Jens Schmidt; Jan D Lünemann
Journal:  Ann Clin Transl Neurol       Date:  2017-05-16       Impact factor: 4.511

Review 4.  The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics.

Authors:  Anjali Patwardhan
Journal:  Cureus       Date:  2020-02-19

Review 5.  Emerging therapeutic options for sporadic inclusion body myositis.

Authors:  Lindsay N Alfano; Linda P Lowes
Journal:  Ther Clin Risk Manag       Date:  2015-09-25       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.